269 related articles for article (PubMed ID: 29226313)
41. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.
Bidstrup TB; Bjørnsdottir I; Sidelmann UG; Thomsen MS; Hansen KT
Br J Clin Pharmacol; 2003 Sep; 56(3):305-14. PubMed ID: 12919179
[TBL] [Abstract][Full Text] [Related]
42. Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
Gu H; Dutreix C; Rebello S; Ouatas T; Wang L; Chun DY; Einolf HJ; He H
Drug Metab Dispos; 2018 Feb; 46(2):109-121. PubMed ID: 29117990
[TBL] [Abstract][Full Text] [Related]
43. Physiologically-Based Pharmacokinetic Model-Informed Drug Development for Fenebrutinib: Understanding Complex Drug-Drug Interactions.
Chen Y; Ma F; Jones NS; Yoshida K; Chiang PC; Durk MR; Wright MR; Jin JY; Chinn LW
CPT Pharmacometrics Syst Pharmacol; 2020 Jun; 9(6):332-341. PubMed ID: 32383787
[TBL] [Abstract][Full Text] [Related]
44. Alectinib: A Review in Advanced, ALK-Positive NSCLC.
Paik J; Dhillon S
Drugs; 2018 Aug; 78(12):1247-1257. PubMed ID: 30030733
[TBL] [Abstract][Full Text] [Related]
45. Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug-Drug Interactions or in Special Populations: An Example Using Tofacitinib.
Tse S; Dowty ME; Menon S; Gupta P; Krishnaswami S
J Clin Pharmacol; 2020 Dec; 60(12):1617-1628. PubMed ID: 32592424
[TBL] [Abstract][Full Text] [Related]
46. Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction Between Clopidogrel and Dasabuvir.
Shebley M; Fu W; Badri P; Bow D; Fischer V
Clin Pharmacol Ther; 2017 Oct; 102(4):679-687. PubMed ID: 28411400
[TBL] [Abstract][Full Text] [Related]
47. Physiologically Based Pharmacokinetic Modeling Approach to Identify the Drug-Drug Interaction Mechanism of Nifedipine and a Proton Pump Inhibitor, Omeprazole.
Le Merdy M; Tan ML; Sun D; Ni Z; Lee SC; Babiskin A; Zhao L
Eur J Drug Metab Pharmacokinet; 2021 Jan; 46(1):41-51. PubMed ID: 33064292
[TBL] [Abstract][Full Text] [Related]
48. Physiologically-Based Pharmacokinetic Predictions of the Effect of Curcumin on Metabolism of Imatinib and Bosutinib: In Vitro and In Vivo Disconnect.
Adiwidjaja J; Boddy AV; McLachlan AJ
Pharm Res; 2020 Jun; 37(7):128. PubMed ID: 32529309
[TBL] [Abstract][Full Text] [Related]
49. Static and Dynamic Projections of Drug-Drug Interactions Caused by Cytochrome P450 3A Time-Dependent Inhibitors Measured in Human Liver Microsomes and Hepatocytes.
Tseng E; Eng H; Lin J; Cerny MA; Tess DA; Goosen TC; Obach RS
Drug Metab Dispos; 2021 Oct; 49(10):947-960. PubMed ID: 34326140
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 2: Investigating Interaction Potential Using a Physiologically Based Pharmacokinetic Model.
Van den Bergh A; Snoeys J; De Zwart L; Ward P; Lopez-Gitlitz A; Ouellet D; Monshouwer M; Chien C
Clin Pharmacokinet; 2020 Sep; 59(9):1149-1160. PubMed ID: 32338346
[TBL] [Abstract][Full Text] [Related]
51. Inhibitory effect of ketoconazole on the pharmacokinetics of a multireceptor tyrosine kinase inhibitor BMS-690514 in healthy participants: assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulations.
Yang Z; Vakkalagadda B; Shen G; Ahlers CM; Has T; Christopher LJ; Kurland JF; Roongta V; Masson E; Zhang S
J Clin Pharmacol; 2013 Feb; 53(2):217-27. PubMed ID: 23436267
[TBL] [Abstract][Full Text] [Related]
52. Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor.
Choo EF; Woolsey S; DeMent K; Ly J; Messick K; Qin A; Takahashi R
Drug Metab Dispos; 2015 Jun; 43(6):864-9. PubMed ID: 25813936
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
Nguyen L; Holland J; Miles D; Engel C; Benrimoh N; O'Reilly T; Lacy S
J Clin Pharmacol; 2015 Sep; 55(9):1012-23. PubMed ID: 25854986
[TBL] [Abstract][Full Text] [Related]
54. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
55. In Vitro Screening of Six Protein Kinase Inhibitors for Time-Dependent Inhibition of CYP2C8 and CYP3A4: Possible Implications with regard to Drug-Drug Interactions.
Filppula AM; Mustonen TM; Backman JT
Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):739-748. PubMed ID: 29956478
[TBL] [Abstract][Full Text] [Related]
56. Physiologically-based pharmacokinetic modeling for mirabegron: a multi-elimination pathway mediated by cytochrome P450 3A4, uridine 5'-diphosphate-glucuronosyltransferase 2B7, and butyrylcholinesterase.
Konishi K; Minematsu T; Nagasaka Y; Tabata K
Xenobiotica; 2019 Aug; 49(8):912-921. PubMed ID: 30301385
[TBL] [Abstract][Full Text] [Related]
57. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases.
Kodama T; Hasegawa M; Takanashi K; Sakurai Y; Kondoh O; Sakamoto H
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1023-8. PubMed ID: 25205428
[TBL] [Abstract][Full Text] [Related]
58. The metabolic drug-drug interaction profile of Dabrafenib: in vitro investigations and quantitative extrapolation of the P450-mediated DDI risk.
Lawrence SK; Nguyen D; Bowen C; Richards-Peterson L; Skordos KW
Drug Metab Dispos; 2014 Jul; 42(7):1180-90. PubMed ID: 24748562
[TBL] [Abstract][Full Text] [Related]
59. Use of a Physiologically Based Pharmacokinetic Model for Quantitative Prediction of Drug-Drug Interactions via CYP3A4 and Estimation of the Intestinal Availability of CYP3A4 Substrates.
Mano Y; Sugiyama Y; Ito K
J Pharm Sci; 2015 Sep; 104(9):3183-93. PubMed ID: 26045365
[TBL] [Abstract][Full Text] [Related]
60. Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model.
Mukherjee D; Zha J; Menon RM; Shebley M
J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):443-456. PubMed ID: 29427135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
